Effects of twenty kinds of chemotherapeutic agents on the proliferation of Treg cells

doi:10.16352/j.issn.1001-6325.2023.10.1518

Abstract

Abstract: Objective To observe the effects of 20 chemotherapeutic agents on the proliferation of Treg cells. Methods Twenty agents used in routine chemotherapy were selected and assayed on IL-2- induced Treg cell proliferation through CellTrace labeling and flow cytometry. Results After treatment with 12 chemotherapeutic agents at non-cytotoxic concentration, the proportion as well as the number of Foxp3⁺Treg cells in CD4⁺ T cells were significantly reduced. Conclusions Twelve chemotherapeutic agents including 3 tubulin interfering agents, 3 transcription and RNA synthesis interfering agents and 2 topoisomerase inhibitors inhibited the proliferation of Treg cells.

Key words: cancer immunity, chemotherapy, Treg cell

CLC Number:

R979.1

HUANG Wei, LING Ruiyun, GAO Lexin, TANG Wen, QIAN Lingbo, CHEN Fengyang. Effects of twenty kinds of chemotherapeutic agents on the proliferation of Treg cells[J]. Basic & Clinical Medicine, 2023, 43(10): 1518-1521.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.10.1518

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I10/1518

References

[1]Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression-implications for anticancer therapy[J]. Nat Rev Clin Oncol, 2019, 16: 356-371.
[2]Minohara K, Imai M, Matoba T, et al. Mature dendritic cells enriched in regulatory molecules may control regulatory T cells and the prognosis of head and neck cancer[J]. Cancer Sci, 2023,114:1256-1269.
[3]Mehraj U, Dar AH, Wani NA, et al. Tumor microenvironment promotes breast cancer chemoresistance[J]. Cancer Chemother Pharmacol, 2021,87:147-158.
[4]Galluzzi L, Buqué A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anti-cancer agents[J]. Cancer Cell,2015,28:690-714.
[5]Li P, Chen F, Zheng J, et al. Cyclophosphamide abrogates the expansion of CD4⁺Foxp3⁺ regulatory T cells and enhances the efficacy of bleomycin in the treatment of mouse B16-F10 melanomas[J]. Cancer Biol Med, 2021,18:1010-1020.
[6]Dees S, Ganesan R, Singh S, et al. Regulatory T cell targeting in cancer: emerging strategies in immunotherapy[J]. Eur J Immunol, 2021,51:280-291.
[7]Eriksson E, Wenthe J, Irenaeus S, et al. Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer[J]. J Transl Med, 2016,14:282.doi:10.1186/s12967-016-1037-z.
[8]Li JY, Duan XF, Wang LP, et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer[J]. J Immunol Res, 2014,2014:286170.doi: 10.1155/2014/286170.doi: 10.1155/2014/286170.
[9]Zhang L, Dermawan K, Jin M, et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy[J]. Clin Immunol, 2008,129:219-229.
[10]Kashima H, Momose F, Umehara H, et al. Epirubicin, identified using a novel luciferase reporter assay for Foxp3 inhibitors, inhibits regulatory T cell activity[J]. PLoS One, 2016,11:e0156643.doi: 10.1371/journal.pone.0156643.
[11]Ning T, Li J, He Y, et al. Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer[J]. Mol Ther, 2021,29:2723-2736.
[12]Ye C, Brand D, Zheng SG. Targeting IL-2: an unex-pected effect in treating immunological diseases [J]. Signal Transduct Target Ther, 2018,3:2.doi: 10.1038/s41392-017-0002-5.